title: Pneumococcal vaccination in a remote population of high-risk Alaska Natives.
abstract: In response to an increasing prevalence of serious pneumococcal disease among adult Alaska Natives of northwest Alaska, a 3-year program was begun in 1987 to identify residents of that remote region who were at high risk for developing invasive pneumococcal disease, to determine their pneumococcal vaccination status, and to deliver vaccine to at least 80 percent of those at risk. After reviewing public health nursing and Indian Health Service data bases, the authors identified 1,337 persons, 20 percent of the 6,692 residents of the region, at high risk for invasive pneumococcal infection, defined either by having a specific chronic disease or by age criteria. Cardiovascular disease and alcoholism were the two most common chronic diseases. Only 30 percent of those determined to be at high risk had received one or more doses of pneumococcal vaccine previously. Half of those persons had received their most recent vaccination 6 or more years earlier. The program used both customary and innovative methods to deliver 23-valent polysaccharide vaccine to 1,046 of those at high risk (78 percent), including 388 persons who were revaccinated. At the completion of the project, 1,123 persons, 84 percent of those at high risk, had received at least 1 dose. They included 1,088 persons, 81 percent of those at high risk, with vaccination within the previous 5 years as a result of the project, compared with a 15-percent rate prior to the vaccination phase of the project. The program demonstrated that high levels of vaccination against pneumococcal disease, exceeding Year 2000 objectives of 60 percent, are attainable in a remote rural Alaskan population.
authors.affiliation: Alaska Native Medical Center, Department of Medicine, Anchorage 99501.
authors.forename: M
authors.initials: M
authors.lastname: Davidson
authors.forename: C
authors.initials: C
authors.lastname: Chamblee
authors.forename: H G
authors.initials: HG
authors.lastname: Campbell
authors.forename: L R
authors.initials: LR
authors.lastname: Bulkow
authors.forename: G E
authors.initials: GE
authors.lastname: Taylor
authors.forename: A P
authors.initials: AP
authors.lastname: Lanier
authors.forename: J
authors.initials: J
authors.lastname: Berner
authors.forename: J S
authors.initials: JS
authors.lastname: Spika
authors.forename: W W
authors.initials: WW
authors.lastname: Williams
authors.forename: J P
authors.initials: JP
authors.lastname: Middaugh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000413:Alaska; D001428:Bacterial Vaccines / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D016208:Databases, Factual; D005260:Female; D006801:Humans; D004930:Inuit; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000208:ethnology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines; D012307:Risk Factors; D012424:Rural Population; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014611:Vaccination
chemical_list: D001428:Bacterial Vaccines; D022242:Pneumococcal Vaccines